Quetiapine for the treatment of generalised anxiety disorder
 
Status Suspended
Process STA
Referral date 01 June 2010
Topic area
  • Mental health and behavioural conditions
  • Public health
Description

Scoped within Batch 10

NICE has been informed by the manufacturer, AstraZeneca, that they have withdrawn their licensing application for the above indication. Therefore this topic has been suspended and the committee discussion that was due to take place on 24 March 2011 has been cancelled.

We will continue to monitor any development and update this webpage if the situation changes.

Provisional Schedule

Closing date for invited submissions / evidence submission: 9 December 2010
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: Liz Walker
Technical Lead: Raisa Sidhu

Consultees

Manufacturers/sponsors AstraZeneca (quetiapine)
Others Department of Health
  Welsh Assembly Government
Patient/carer groups Anxiety UK
Professional groups British Association for Psychopharmacology
  Royal College of Nursing
  Royal College of Pathologists

Commentators

Associated guideline groups None
Associated public health groups None
Comparator manufacturers Dr Reddy's Laboratories (fluoxetine, sertraline)
  Eli Lilly (duloxetine, fluoxetine)
  Pfizer (pregabalin, venlafaxine, sertraline, mirtazapine, paroxetine)
Evidence review group National Institute for Health Research Health Technology Assessment Programme
  School of Health & Related Research Sheffield (ScHARR)
General British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
Relevant research groups None

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance